Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

The pharmacokinetics of high dose metoclopramide in patients with neoplastic disease.

Tytuł:
The pharmacokinetics of high dose metoclopramide in patients with neoplastic disease.
Autorzy:
Bryson SM
McGovern EM
Kelman AW
White K
Addis GJ
Whiting B
Źródło:
British journal of clinical pharmacology [Br J Clin Pharmacol] 1985 Jun; Vol. 19 (6), pp. 757-66.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: Oxford : Wiley-Blackwell
Original Publication: London, Macmillan Journals Ltd.
MeSH Terms:
Metoclopramide/*metabolism
Neoplasms/*metabolism
Aged ; Humans ; Kinetics ; Male ; Metabolic Clearance Rate ; Middle Aged
References:
Drugs. 1976;12(2):81-131. (PMID: 786607)
Gastroenterology. 1977 May;72(5 Pt 1):864-9. (PMID: 849817)
Br J Clin Pharmacol. 1978 Nov;6(5):401-7. (PMID: 728283)
Br J Clin Pharmacol. 1979 Nov;8(5):469-74. (PMID: 508553)
Br J Clin Pharmacol. 1980 Apr;9(4):371-7. (PMID: 7378253)
Br J Clin Pharmacol. 1984 Nov;18(5):679-84. (PMID: 6508977)
J Pharmacokinet Biopharm. 1980 Oct;8(5):497-507. (PMID: 7252793)
N Engl J Med. 1981 Oct 15;305(16):905-9. (PMID: 7024807)
Eur J Clin Pharmacol. 1981;20(6):465-71. (PMID: 7286058)
Clin Pharmacokinet. 1983 Nov-Dec;8(6):523-9. (PMID: 6360466)
J Clin Hosp Pharm. 1984 Sep;9(3):263-6. (PMID: 6490946)
Eur J Clin Pharmacol. 1981;19(6):437-41. (PMID: 7250177)
Substance Nomenclature:
L4YEB44I46 (Metoclopramide)
Entry Date(s):
Date Created: 19850601 Date Completed: 19851001 Latest Revision: 20190511
Update Code:
20240104
PubMed Central ID:
PMC1463881
DOI:
10.1111/j.1365-2125.1985.tb02711.x
PMID:
4027119
Czasopismo naukowe
High dose metoclopramide infusions (10 mg/kg) were administered to nineteen patients with bronchial carcinoma who were receiving intravenous cyclophosphamide as single agent chemotherapy. Considerable interindividual variability in metoclopramide disposition was observed. Mean clearance was 0.33 +/- 0.13 (s.d.) l h-1 kg-1, mean volume of distribution at steady state was 3.8 +/- 1.2 (s.d.) l/kg and mean elimination half-life was 8.3 +/- 4.4 (s.d.) h. These results were significantly different from mean values previously reported for young healthy volunteers given conventional doses (0.70 l h-1 kg-1, 2.2 l/kg and 2.6 h respectively). Significant correlations were found between serum urea, serum creatinine and metoclopramide clearance. The metoclopramide regimens were well tolerated and, with the exception of two patients, were completely effective in the prevention of nausea and vomiting. To achieve and maintain target serum metoclopramide concentrations of 1 microgram/ml, we now administer a loading infusion of 3.61 mg/kg over 30 min followed by a maintenance infusion of 0.36 mg kg-1 h-1 for 10 h. Cyclophosphamide is normally administered concurrently with the second infusion. For patients with evidence of mild renal impairment, the maintenance infusion rate of metoclopramide hydrochloride should be adjusted according to the predicted individual clearance value; CL (l h-1 kg-1) = 0.57 - [0.036 X urea (mmol/l)].

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies